Immune Memory to Sudan Virus: Comparison between Two Separate Disease Outbreaks

Viruses

Volumn 7, Issue 1, 2015, Pages 37-51

  Sobarzo, Ariel ^a   Eskira, Yael ^a   Herbert, Andrew S ^b   Kuehne, Ana I ^b   Stonier, Spencer W ^b   Ochayon, David E ^a   Fedida Metula, Shlomit ^a   Balinandi, Steven ^c   Kislev, Yaara ^a   Tali, Neta ^a   Lewis, Eli C ^a   Lutwama, Julius Julian ^c   Dye, John M ^b   Yavelsky, Victoria ^a   Lobel, Leslie ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

Author keywords

Cross reactivity; Ebolavirus; Human survivors; Memory immunity

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS PROTEIN; CYTOKINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL MEMORY; IMMUNOREACTIVITY; NONHUMAN; PLAQUE REDUCTION NEUTRALIZATION ASSAY; PROTEIN EXPRESSION; SERODIAGNOSIS; SUDAN VIRUS; SUDAN VIRUS INFECTION; VIRUS NEUTRALIZATION; BLOOD; CELLULAR IMMUNITY; COHORT ANALYSIS; EBOLAVIRUS; EPIDEMIC; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; SECRETION (PROCESS); SUDAN; SURVIVOR; UGANDA;

EBOLA VIRUS;

ANTIBODIES, VIRAL; COHORT STUDIES; CROSS REACTIONS; CYTOKINES; DISEASE OUTBREAKS; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; NEUTRALIZATION TESTS; SUDAN; SURVIVORS; UGANDA;

EID: 84920540653     PISSN: 19994915     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7010037     Document Type: Article

References (29)

1. Kuhn, J.H. Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies. Arch. Virol. Suppl. 2008, 20, 13–360.
2. Ascenzi, P.; Bocedi, A.; Heptonstall, J.; Capobianchi, M.R.; di Caro, A.; Mastrangelo, E.; Bolognesi, M.; Ippolito, G. Ebolavirus and marburgvirus: Insight the filoviridae family. Mol. Aspects Med. 2008, 29, 151–185.
3. Feldmann, H.; Geisbert, T.W. Ebola haemorrhagic fever. Lancet 2011, 377, 849–862.
4. Dolnik, O.; Kolesnikova, L.; Becker, S. Filoviruses: Interactions with the host cell. Cell. Mol. Life Sci. 2008, 65, 756–776.
5. Albarino, C.G.; Shoemaker, T.; Khristova, M.L.; Wamala, J.F.; Muyembe, J.J.; Balinandi, S.; Tumusiime, A.; Campbell, S.; Cannon, D.; Gibbons, A.; et al. Genomic analysis of filoviruses associated with four viral hemorrhagic fever outbreaks in uganda and the democratic republic of the congo in 2012. Virology 2013, 442, 97–100.
6. Anonymous. Outbreak of Ebola Hemorrhagic Fever—Uganda, August 2000–January 2001. Can. Commun. Dis. Rep. 2001, 27, 49–53.
7. Mohamadzadeh, M.; Chen, L.; Schmaljohn, A.L. How ebola and marburg viruses battle the immune system. Nat. Rev. Immunol. 2007, 7, 556–567.
8. Kondratowicz, A.S.; Maury, W.J. Ebolavirus: A brief review of novel therapeutic targets. Future Microbiol. 2012, 7, 1–4.
9. Gupta, M.; Goldsmith, C.S.; Metcalfe, M.G.; Spiropoulou, C.F.; Rollin, P.E. Reduced virus replication, proinflammatory cytokine production, and delayed macrophage cell death in human pbmcs infected with the newly discovered bundibugyo ebolavirus relative to zaire ebolavirus. Virology 2010, 402, 203–208.
10. Sanchez, A.; Lukwiya, M.; Bausch, D.; Mahanty, S.; Sanchez, A.J.; Wagoner, K.D.; Rollin, P.E. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: Cellular responses, virus load, and nitric oxide levels. J. Virol. 2004, 78, 10370–10377.
11. Wauquier, N.; Becquart, P.; Gasquet, C.; Leroy, E.M. Immunoglobulin G in Ebola outbreak survivors, Gabon. Emerg. Infect. Dis. 2009, 15, 1136–1137.
12. Sobarzo, A.; Ochayon, D.E.; Lutwama, J.J.; Balinandi, S.; Guttman, O.; Marks, R.S.; Kuehne, A.I.; Dye, J.M.; Yavelsky, V.; Lewis, E.C.; et al. Persistent immune responses after ebola virus infection. N. Engl. J. Med. 2013, 369, 492–493.
13. Lamunu, M.; Lutwama, J.J.; Kamugisha, J.; Opio, A.; Nambooze, J.; Ndayimirije, N.; Okware, S. Containing a haemorrhagic fever epidemic: The ebola experience in uganda (October 2000–January 2001). Int. J. Infect. Dis. 2004, 8, 27–37.
14. Sobarzo, A.; Groseth, A.; Dolnik, O.; Becker, S.; Lutwama, J.J.; Perelman, E.; Yavelsky, V.; Muhammad, M.; Kuehne, A.I.; Marks, R.S.; et al. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of sudan ebolavirus (gulu). J. Infect. Dis. 2013, 208, 299–309.
15. Sobarzo, A.; Perelman, E.; Groseth, A.; Dolnik, O.; Becker, S.; Lutwama, J.J.; Dye, J.M.; Yavelsky, V.; Lobel, L.; Marks, R.S. Profiling the native specific human humoral immune response to Sudan Ebola virus strain gulu by chemiluminescence enzyme-linked immunosorbent assay. Clin. Vaccine Immunol. 2012, 19, 1844–1852.
16. Dias, J.M.; Kuehne, A.I.; Abelson, D.M.; Bale, S.; Wong, A.C.; Halfmann, P.; Muhammad, M.A.; Fusco, M.L.; Zak, S.E.; Kang, E.; et al. Ashared structural solution for neutralizing ebolaviruses. Nat. Struct. Mol. Biol. 2011, 18, 1424–1427.
17. Kohavi, R. A study of cross. In Proceedings of the 14th International Joint Conference on Artifcial Intelligence (IJCAI). Morgan Kaufmann Publishers Inc.: San Francisco, CA, USA, 1995.
18. Paweska, J.T.; Burt, F.J.; Swanepoel, R. Validation of igg-sandwich and igm-capture elisa for the detection of antibody to rift valley fever virus in humans. J. Virol. Methods 2005, 124, 173–181.
19. Swenson, D.L.; Wang, D.; Luo, M.; Warfield, K.L.; Woraratanadharm, J.; Holman, D.H.; Dong, J.Y.; Pratt, W.D. Vaccine to confer to nonhuman primates complete protection against multistrain ebola and marburg virus infections. Clin. Vaccine Immunol. 2008, 15, 460–467.
20. Cavelti-Weder, C.; Babians-Brunner, A.; Keller, C.; Stahel, M.A.; Kurz-Levin, M.; Zayed, H.; Solinger, A.M.; Mandrup-Poulsen, T.; Dinarello, C.A.; Donath, M.Y. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012, 35, 1654–1662.
21. Dye, J.M.; Herbert, A.S.; Kuehne, A.I.; Barth, J.F.; Muhammad, M.A.; Zak, S.E.; Ortiz, R.A.; Prugar, L.I.; Pratt, W.D. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. PNAS 2012, 109, 5034–5039.
22. Sullivan, N.J.; Martin, J.E.; Graham, B.S.; Nabel, G.J. Correlates of protective immunity for Ebola vaccines: Implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 2009, 7, 393–400.
23. Shedlock, D.J.; Aviles, J.; Talbott, K.T.; Wong, G.; Wu, S.J.; Villarreal, D.O.; Myles, D.J.; Croyle, M.A.; Yan, J.; Kobinger, G.P.; et al. Induction of broad cytotoxic t cells by protective DNA vaccination against marburg and Ebola. Mol. Ther. 2013, 21, 1432–1444.
24. Marzi, A.; Yoshida, R.; Miyamoto, H.; Ishijima, M.; Suzuki, Y.; Higuchi, M.; Matsuyama, Y.; Igarashi, M.; Nakayama, E.; Kuroda, M.; et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One 2012, 7, e36192.
25. Baize, S.; Leroy, E.M.; Georges-Courbot, M.C.; Capron, M.; Lansoud-Soukate, J.; Debre, P.; Fisher-Hoch, S.P.; McCormick, J.B.; Georges, A.J. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in ebola virus-infected patients. Nat. Med. 1999, 5, 423–426.
26. Wong, G.; Richardson, J.S.; Pillet, S.; Patel, A.; Qiu, X.; Alimonti, J.; Hogan, J.; Zhang, Y.; Takada, A.; Feldmann, H.; et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci. Transl. Med. 2012, 4, 158ra146.
27. Wong, G.; Kobinger, G.P.; Qiu, X. Characterization of host immune responses in ebola virus infections. Expert Rev. Clin. Immunol. 2014, 10, 781–790.
28. Hoenen, T.; Groseth, A.; Feldmann, H. Current Ebola vaccines. Expert Opin. Biol. Ther. 2012, 12, 859–872.
29. Sullivan, N.J.; Hensley, L.; Asiedu, C.; Geisbert, T.W.; Stanley, D.; Johnson, J.; Honko, A.; Olinger, G.; Bailey, M.; Geisbert, J.B.; et al. Cd8+ cellular immunity mediates rad5 vaccine protection against ebola virus infection of nonhuman primates. Nat. Med. 2011, 17, 1128–1131.